CASI Pharmaceuticals CASIF Income Statement (2021-2025)

OTC CASIF
$0.13 -0.01 (-7.14%)
At close: Aug 19, 2026 · 4:00 PM EDT
1Y3Y5Y7Y10YAll
Download Data
Income Statement Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter) 9.03M8.55M10.21M10.26M8.35M9.82M8.84M6.87M3.41M3.98M7.79M13.36M6.24M4.17M3.08M7.22M
Cost of Revenue (Quarter) 3.76M3.55M4.25M4.27M3.38M3.99M3.65M2.81M1.60M1.91M3.75M10.13M2.62M2.12M2.37M3.53M
Gross Profit (Quarter) 5.30M5.02M5.97M10.99M4.97M5.83M5.19M4.06M1.81M2.07M4.04M3.23M3.62M2.06M0.71M3.69M
Operating items
Research & Development (Quarter) 3.99M3.85M3.90M-27.74M2.53M2.61M2.40M8.90M-2.48M-1.25M-1.52M23.12M-1.94M-1.72M-1.41M1.24M
Selling, General & Administrative (Quarter) 5.33M5.52M4.85M-39.14M5.75M7.70M5.52M6.42M-4.81M-5.94M-5.70M40.03M-7.70M-6.08M-4.93M9.56M
Other Operating Expenses (Quarter) 2.94M2.04M2.93M-29.78M3.90M4.86M2.37M-7.84M-3.97M0.50M-0.02M0.01M-5.38M-5.04M5.72M
Operating Expenses (Quarter) 12.26M11.41M11.68M-96.67M12.18M15.18M10.29M7.49M-11.26M-10.86M-12.51M85.39M-14.00M-13.18M-11.38M16.51M
Operating Income (Quarter) -6.96M-6.39M-5.72M-14.97M-7.21M-9.35M-5.09M-3.43M-9.45M-8.79M-8.46M-12.91M-10.38M-11.12M-10.68M-77.19M
EBIT (Quarter) -6.96M-6.39M-5.72M-14.97M-7.21M-9.35M-5.09M-3.43M-9.45M-8.79M-8.46M-12.91M-10.38M-11.12M-10.68M-77.19M
Non-operating items
Non Operating Investment Income (Quarter) -0.14M-0.17M-0.27M
Interest & Investment Income (Quarter) 0.13M0.14M0.14M0.13M0.08M0.04M0.01M
Other Non Operating Income (Quarter) 0.04M0.01M0.01M-0.02M1.34M0.01M0.47M-2.74M0.16M0.02M-0.01M0.02M0.02M0.01M-0.43M-0.01M
Non Operating Income (Quarter) -0.01M-0.16M0.16M-0.52M-0.19M-0.19M-0.20M-0.28M-0.20M-0.24M-0.20M-1.48M
Net income details
EBT (Quarter) -6.96M-6.39M-5.72M-100.47M-7.21M-9.35M-5.09M-64.71M-9.32M-8.65M-8.32M-13.02M-10.30M-11.08M-10.67M-77.55M
Profit After Tax (Quarter) -8.40M-7.49M-5.02M-19.34M-5.83M-10.07M-4.47M-6.59M9.53M-6.96M-8.39M-14.37M10.75M-13.38M-10.88M-83.07M
Income from Non-Controlling Interests (Quarter) -0.42M-0.55M-0.74M-7.04M-0.67M-0.59M-0.60M-0.74M
Income from Continuing Operations (Quarter) -6.96M-6.39M-5.72M-100.47M-7.21M-9.35M-5.09M-64.71M-9.32M-8.65M-8.32M-13.02M-10.30M-11.08M-10.67M-77.55M
Income from Discontinued Operations (Quarter) 0.08M
Consolidated Net Income (Quarter) -6.96M-6.39M-5.72M-100.47M-7.21M-9.27M-5.09M-64.71M-9.32M-8.65M-8.32M-13.02M-10.30M-11.08M-10.67M-77.55M
Income towards Parent Company (Quarter) -6.96M-6.39M-5.72M-100.47M-7.21M-9.27M-5.09M-64.71M-9.32M-8.65M-8.32M-13.02M-10.30M-11.08M-10.67M-77.55M
Preferred Dividend Payments (Quarter) 0.61M0.73M0.92M7.23M0.84M0.76M0.77M0.91M
Net Income towards Common Stockholders (Quarter) -7.57M-7.13M-6.63M-107.70M-8.06M-10.03M-5.86M-65.61M-9.32M-8.65M-8.32M-13.02M-10.30M-11.08M-10.67M-77.55M
Additional items
EPS (Basic) (Quarter) -0.55-0.52-0.49-7.89-0.60-0.75-0.44-4.91-0.70-0.64-0.54-0.85-0.66-0.71-0.66-4.18
EPS (Diluted) (Quarter) -0.56-0.52-0.49-7.89-0.59-0.73-0.43-4.91-0.70-0.65-0.62-0.85-0.67-0.72-0.70-4.18
Shares Outstanding (Quarter) 13.61M13.80M13.70M13.67M13.65M13.34M13.34M13.38M13.36M13.38M13.52M15.29M15.34M15.49M15.51M16.05M18.54M
Shares Outstanding (Diluted) (Quarter) 13.61M13.61M13.61M13.61M13.65M13.65M13.65M13.65M13.36M13.36M13.36M13.36M15.34M15.34M15.34M15.34M18.54M
Shares Outstanding (Entity) (Quarter) 1.36M1.38M1.37M1.37M1.36M1.33M1.33M1.34M1.34M1.34M1.35M1.53M1.53M1.55M1.55M1.60M1.85M
EBITDA (Quarter) -6.96M-6.39M-5.72M-14.97M-7.21M-9.35M-5.09M-3.43M-9.45M-8.79M-8.46M-12.91M-10.38M-11.12M-10.68M-77.19M
Interest Expenses (Quarter) 83.65M85.50M61.28M0.23M0.35M